Dr. John N. Gnabre was a visionary scientist, respected colleague, and generous mentor.

Dr. John Gnabre (d. 2019). Gnabre, a visionary scientist, was a pharmacologist, toxicologist, decorated Johns Hopkins University AIDS researcher, and founder of the Baltimore based biotech company Mal-4 Research Institute which focused on developing botanical drugs to combat cancer and infectious diseases.

“Dr. Gnabre was uncompromising in his zeal to harness the healing powers of nature…”

Dr. Gnabre was uncompromising in his zeal to harness the healing powers of nature through proving their effects advancing molecular sciences. He was a pioneer in patenting a scientifically proven natural herbal medicine to treat viral diseases via a process we now call The Gnabre Method.

Inspired by the global call-to-action for a solution, leadership from the John Gnabre Science Research Institute (formerly the Mal-4 Research Institute) engaged V-Formation Ventures, an Atlanta, Georgia based venture strategy advisory consultancy, to assist in orchestrating their response. The result is the establishment of a “clinical accelerator” to test our botanical drugs against COVID-19; while also structuring our clinical trials to be fully inclusive of communities often overlooked in the fight for a COVID cure via the Clinical Outreach for Researchers and Organizations Networked to Achieve Victory (C.O.R.O.N.A. V.) Project™.

The C.O.R.O.N.A. V. Project is a clinical outreach initiative to address the COVID-19 crisis with specific emphasis on reaching the Black, Indigenous and People of Color (BIPOC) communities.

When successful, through the COVID-19 Clinical Accelerator®, the C.O.R.O.N.A. V. Project™ will produce clinical trials whose outcomes could result in the following:

  1. Produce one or more clinically proven therapeutics to treat COVID-19.
  2. Deliver a clinically proven therapeutic that will cease the morbidity from COVID-19 infection.
  3. Create health equity by reducing COVID-19 infections in BIPOC communities.
  4. Create health equity by reducing COVID-19 infection related deaths in in BIPOC communities.
  5. Produce COVID-19 clinical trials which are representative and inclusive of BIPOC communities.
  6. Deliver a ‘best practices’ blueprint for collaborative clinical engagement that yields adequate participation from BIPOC communities.